As the result of a rhJNK1 HTS, the imidazo [1, 2-a] quinoxaline 1 was identified as a 1.6 μM
rhJNK1 inhibitor. Optimization of this compound lead to AX13587 (rhJNK1 IC 50= 160 nM) …

Potent JNK3 isoform selective inhibitors were developed from a thiophenyl-pyrazolourea
scaffold. Through structure activity relationship (SAR) studies utilizing enzymatic and cell …

A series of 1-aryl-3, 4-dihydroisoquinoline inhibitors of JNK3 are described. Compounds 20
and 24 are the most potent inhibitors (pIC50 7.3 and 6.9, respectively in a radiometric filter …

A series of N-benzylated isatin oximes were developed as inhibitors of the mitogen-activated
kinase, JNK3. X-ray crystallographic structures aided in the design and synthesis of novel …

The c-jun N-terminal kinase 3 (JNK3) is expressed primarily in the brain. Numerous reports
have shown that inhibition of JNK3 is a promising strategy for treatment of …

The identification and exploration of a novel, potent and selective series of N-(3-cyano-4, 5,
6, 7-tetrahydro-1-benzothien-2-yl) amide inhibitors of JNK2 and JNK3 kinases is described …

The mitogen-activated kinases JNK1/2/3 are key enzymes in signaling modules that
transduce and integrate extracellular stimuli into coordinated cellular response. Here, we …

The JNK–JIP1 interaction represents an attractive target for the selective inhibition of JNK-
mediated signaling. We report a virtual screening (VS) workflow, based on a combination of …

The c‐jun N‐terminal kinase (JNK) signaling pathway is regulated by JNK‐interacting
protein‐1 (JIP1), which is a scaffolding protein assembling the components of the JNK …

Abstract c-Jun N-terminal kinase (JNK) signalling regulates both cancer cell apoptosis and
survival. Emerging evidence show that JNK promoted tumour progression is involved in …